Libtayo

Regeneron Pharmaceuticals is a leading biotechnology company that discovers, develops, and commercializes medicines for serious diseases. The company is renowned for its proprietary VelociSuite technology platforms, which accelerate the drug development process by using genetically engineered mice to produce fully human monoclonal antibodies. Its commercial portfolio includes blockbuster treatments such as Eylea for retinal diseases, Dupixent for inflammatory conditions (developed with Sanofi), and Libtayo for various oncology indications. Regeneron maintains a robust pipeline across oncology, immunology, infectious diseases, and rare genetic disorders. The company is headquartered in Tarrytown, New York, and operates significant manufacturing facilities in both the United States and Ireland.